Earnings summaries and quarterly performance for PMV Pharmaceuticals.
Executive leadership at PMV Pharmaceuticals.
Board of directors at PMV Pharmaceuticals.
Research analysts covering PMV Pharmaceuticals.
Recent press releases and 8-K filings for PMVP.
PMV Pharmaceuticals Reports Q3 2025 Financial Results and Positive Clinical Data
PMVP
Earnings
Guidance Update
New Projects/Investments
- PMV Pharmaceuticals, Inc. reported $129.3 million in cash, cash equivalents, and marketable securities as of September 30, 2025, providing an expected cash runway to the end of the first quarter of 2027.
- The company announced updated clinical results from the Phase 2 pivotal portion of the PYNNACLE study for rezatapopt, observing a 34% overall response rate (ORR) among 103 evaluable patients across all cohorts, with a median duration of response of 7.6 months.
- In the ovarian cancer cohort, a 46% ORR was observed among 48 evaluable patients, with a median duration of response of 8.0 months.
- PMV Pharma plans to submit a New Drug Application (NDA) for rezatapopt for platinum-resistant/refractory ovarian cancer in the first quarter of 2027.
Nov 12, 2025, 1:00 PM
PMV Pharmaceuticals Announces Updated Rezatapopt Phase 2 Clinical Trial Data
PMVP
New Projects/Investments
Product Launch
- PMV Pharmaceuticals reported updated interim data from its Phase 2 PYNNACLE clinical trial for rezatapopt, showing a 34% overall response rate (ORR) among 103 evaluable patients across all cohorts, with a median duration of response of 7.6 months.
- In the ovarian cancer cohort, rezatapopt achieved a 46% ORR among 48 evaluable patients, with a median duration of response of 8.0 months.
- The company plans to submit a New Drug Application (NDA) for rezatapopt for platinum-resistant/refractory ovarian cancer in the first quarter of 2027.
- Treatment-related adverse events were mostly Grade 1-2, with a drug discontinuation rate of 3.6% due to TRAEs.
Oct 24, 2025, 3:39 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more